MedTrace Logo

A Study to Evaluate Treatment Adherence in Schizophrenia With Long Acting Risperidone Microspheres (e-STAR)

NCT00294008 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 230

Last updated 2014-04-03

No results posted yet for this study

Summary

This study is a non-interventional web based registry designed to assess demographic, treatment and outcomes data in patients receiving treatment with long-acting injectable risperidone. One year retrospective data and 2 year prospective data will be collected.

Conditions

  • Schizophrenia
  • Tranquilizing Agents
  • Mental Disorders
  • Therapeutic Uses
  • Physiological Effects of Drugs
  • Psychotropic Drugs
  • Antipsychotic Agents

Interventions

DRUG

Risperdal Consta

flexible dosage for 24 months

Sponsors & Collaborators

  • Janssen Korea, Ltd., Korea

    lead INDUSTRY

Principal Investigators

  • Janssen Korea, Ltd. Clinical Trial · Janssen Korea, Ltd.

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-12-31
Primary Completion
2009-06-30
Completion
2009-06-30

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00294008 on ClinicalTrials.gov